

Non-Tyrosine Kinase Inhibitors Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

<https://marketpublishers.com/r/N2C8E988FAD7EN.html>

Date: January 2021

Pages: 104

Price: US\$ 3,000.00 (Single User License)

ID: N2C8E988FAD7EN

Abstracts

SUMMARY

Further key aspects of the report indicate that:

Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology

Chapter 2: Global Industry Summary

Chapter 3: Market Dynamics

Chapter 4: Global Market Segmentation by region, type and End-Use

Chapter 5: North America Market Segmentation by region, type and End-Use

Chapter 6: Europe Market Segmentation by region, type and End-Use

Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use

Chapter 8: South America Market Segmentation by region, type and End-Use

Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.

Chapter 10: Market Competition by Companies

Chapter 11: Market forecast and environment forecast.

Chapter 12: Industry Summary.

The global Non-Tyrosine Kinase Inhibitors market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.

Based on the type of product, the global Non-Tyrosine Kinase Inhibitors market segmented into

mTOR Inhibitors

RAF/MEK Inhibitors

CDK Inhibitors

Based on the end-use, the global Non-Tyrosine Kinase Inhibitors market classified into

Liver Cancer

Respiratory Cancer

Brain Cancer

Others

Based on geography, the global Non-Tyrosine Kinase Inhibitors market segmented into

North America [U.S., Canada, Mexico]

Europe [Germany, UK, France, Italy, Rest of Europe]

Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]

South America [Brazil, Argentina, Rest of Latin America]

Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]

And the major players included in the report are

Roche

Eli Lilly

Novartis

Array BioPharma

Nerviano Medical Sciences

Pfizer

Merck KGaA

Astex Pharmaceuticals

Cyclacel Pharmaceuticals

Daiichi Sankyo

Onconova Therapeutics

AstraZeneca

GlaxoSmithKline (GSK)

Carna Biosciences

Celgene Corporation

Eternity Bioscience

Jasco Pharmaceuticals

Contents

1 RESEARCH SCOPE

- 1.1 Research Product Definition
- 1.2 Research Segmentation
 - 1.2.1 Product Type
 - 1.2.2 Main product Type of Major Players
- 1.3 Demand Overview
- 1.4 Research Methodology

2 GLOBAL NON-TYROSINE KINASE INHIBITORS INDUSTRY

- 2.1 Summary about Non-Tyrosine Kinase Inhibitors Industry
- 2.2 Non-Tyrosine Kinase Inhibitors Market Trends
 - 2.2.1 Non-Tyrosine Kinase Inhibitors Production & Consumption Trends
 - 2.2.2 Non-Tyrosine Kinase Inhibitors Demand Structure Trends
- 2.3 Non-Tyrosine Kinase Inhibitors Cost & Price

3 MARKET DYNAMICS

- 3.1 Manufacturing & Purchasing Behavior in 2020
- 3.2 Market Development under the Impact of COVID-19
 - 3.2.1 Drivers
 - 3.2.2 Restraints
 - 3.2.3 Opportunity
 - 3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

- 4.1 Region Segmentation (2017 to 2021f)
 - 4.1.1 North America (U.S., Canada and Mexico)
 - 4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
 - 4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
 - 4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
 - 4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
- 4.2 Product Type Segmentation (2017 to 2021f)

- 4.2.1 mTOR Inhibitors
- 4.2.2 RAF/MEK Inhibitors
- 4.2.3 CDK Inhibitors
- 4.3 Consumption Segmentation (2017 to 2021f)
 - 4.3.1 Liver Cancer
 - 4.3.2 Respiratory Cancer
 - 4.3.3 Brain Cancer
 - 4.3.4 Others

5 NORTH AMERICA MARKET SEGMENT

- 5.1 Region Segmentation (2017 to 2021f)
 - 5.1.1 U.S.
 - 5.1.2 Canada
 - 5.1.3 Mexico
- 5.2 Product Type Segmentation (2017 to 2021f)
 - 5.2.1 mTOR Inhibitors
 - 5.2.2 RAF/MEK Inhibitors
 - 5.2.3 CDK Inhibitors
- 5.3 Consumption Segmentation (2017 to 2021f)
 - 5.3.1 Liver Cancer
 - 5.3.2 Respiratory Cancer
 - 5.3.3 Brain Cancer
 - 5.3.4 Others
- 5.4 Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

- 6.1 Region Segmentation (2017 to 2021f)
 - 6.1.1 Germany
 - 6.1.2 UK
 - 6.1.3 France
 - 6.1.4 Italy
 - 6.1.5 Rest of Europe
- 6.2 Product Type Segmentation (2017 to 2021f)
 - 6.2.1 mTOR Inhibitors
 - 6.2.2 RAF/MEK Inhibitors
 - 6.2.3 CDK Inhibitors
- 6.3 Consumption Segmentation (2017 to 2021f)

- 6.3.1 Liver Cancer
- 6.3.2 Respiratory Cancer
- 6.3.3 Brain Cancer
- 6.3.4 Others
- 6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

- 7.1 Region Segmentation (2017 to 2021f)
 - 7.1.1 China
 - 7.1.2 India
 - 7.1.3 Japan
 - 7.1.4 South Korea
 - 7.1.5 Southeast Asia
 - 7.1.6 Australia
 - 7.1.7 Rest of Asia Pacific
- 7.2 Product Type Segmentation (2017 to 2021f)
 - 7.2.1 mTOR Inhibitors
 - 7.2.2 RAF/MEK Inhibitors
 - 7.2.3 CDK Inhibitors
- 7.3 Consumption Segmentation (2017 to 2021f)
 - 7.3.1 Liver Cancer
 - 7.3.2 Respiratory Cancer
 - 7.3.3 Brain Cancer
 - 7.3.4 Others
- 7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

- 8.1 Region Segmentation (2017 to 2021f)
 - 8.1.1 Brazil
 - 8.1.2 Argentina
 - 8.1.3 Rest of Latin America
- 8.2 Product Type Segmentation (2017 to 2021f)
 - 8.2.1 mTOR Inhibitors
 - 8.2.2 RAF/MEK Inhibitors
 - 8.2.3 CDK Inhibitors
- 8.3 Consumption Segmentation (2017 to 2021f)
 - 8.3.1 Liver Cancer

- 8.3.2 Respiratory Cancer
- 8.3.3 Brain Cancer
- 8.3.4 Others
- 8.4 Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

- 9.1 Region Segmentation (2017 to 2021f)
 - 9.1.1 GCC
 - 9.1.2 North Africa
 - 9.1.3 South Africa
 - 9.1.4 Rest of Middle East and Africa
- 9.2 Product Type Segmentation (2017 to 2021f)
 - 9.2.1 mTOR Inhibitors
 - 9.2.2 RAF/MEK Inhibitors
 - 9.2.3 CDK Inhibitors
- 9.3 Consumption Segmentation (2017 to 2021f)
 - 9.3.1 Liver Cancer
 - 9.3.2 Respiratory Cancer
 - 9.3.3 Brain Cancer
 - 9.3.4 Others
- 9.4 Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

- 10.1 Brief Introduction of Major Players
 - 10.1.1 Roche
 - 10.1.2 Eli Lilly
 - 10.1.3 Novartis
 - 10.1.4 Array BioPharma
 - 10.1.5 Nerviano Medical Sciences
 - 10.1.6 Pfizer
 - 10.1.7 Merck KGaA
 - 10.1.8 Astex Pharmaceuticals
 - 10.1.9 Cyclacel Pharmaceuticals
 - 10.1.10 Daiichi Sankyo
 - 10.1.11 Onconova Therapeutics
 - 10.1.12 AstraZeneca
 - 10.1.13 GlaxoSmithKline (GSK)

- 10.1.14 Carna Biosciences
- 10.1.15 Celgene Corporation
- 10.1.16 Eternity Bioscience
- 10.1.17 Jasco Pharmaceuticals
- 10.2 Non-Tyrosine Kinase Inhibitors Sales Date of Major Players (2017-2020e)
 - 10.2.1 Roche
 - 10.2.2 Eli Lilly
 - 10.2.3 Novartis
 - 10.2.4 Array BioPharma
 - 10.2.5 Nerviano Medical Sciences
 - 10.2.6 Pfizer
 - 10.2.7 Merck KGaA
 - 10.2.8 Astex Pharmaceuticals
 - 10.2.9 Cyclacel Pharmaceuticals
 - 10.2.10 Daiichi Sankyo
 - 10.2.11 Onconova Therapeutics
 - 10.2.12 AstraZeneca
 - 10.2.13 GlaxoSmithKline (GSK)
 - 10.2.14 Carna Biosciences
 - 10.2.15 Celgene Corporation
 - 10.2.16 Eternity Bioscience
 - 10.2.17 Jasco Pharmaceuticals
- 10.3 Market Distribution of Major Players
- 10.4 Global Competition Segmentation

11 MARKET FORECAST

- 11.1 Forecast by Region
- 11.2 Forecast by Demand
- 11.3 Environment Forecast
 - 11.3.1 Impact of COVID-19
 - 11.3.2 Geopolitics Overview
 - 11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT

List Of Tables

LIST OF TABLES

1. Table Non-Tyrosine Kinase Inhibitors Product Type Overview
2. Table Non-Tyrosine Kinase Inhibitors Product Type Market Share List
3. Table Non-Tyrosine Kinase Inhibitors Product Type of Major Players
4. Table Brief Introduction of Roche
5. Table Brief Introduction of Eli Lilly
6. Table Brief Introduction of Novartis
7. Table Brief Introduction of Array BioPharma
8. Table Brief Introduction of Nerviano Medical Sciences
9. Table Brief Introduction of Pfizer
10. Table Brief Introduction of Merck KGaA
11. Table Brief Introduction of Astex Pharmaceuticals
12. Table Brief Introduction of Cyclacel Pharmaceuticals
13. Table Brief Introduction of Daiichi Sankyo
14. Table Brief Introduction of Onconova Therapeutics
15. Table Brief Introduction of AstraZeneca
16. Table Brief Introduction of GlaxoSmithKline (GSK)
17. Table Brief Introduction of Carna Biosciences
18. Table Brief Introduction of Celgene Corporation
19. Table Brief Introduction of Eternity Bioscience
20. Table Brief Introduction of Jasco Pharmaceuticals
21. Table Products & Services of Roche
22. Table Products & Services of Eli Lilly
23. Table Products & Services of Novartis
24. Table Products & Services of Array BioPharma
25. Table Products & Services of Nerviano Medical Sciences
26. Table Products & Services of Pfizer
27. Table Products & Services of Merck KGaA
28. Table Products & Services of Astex Pharmaceuticals
29. Table Products & Services of Cyclacel Pharmaceuticals
30. Table Products & Services of Daiichi Sankyo
31. Table Products & Services of Onconova Therapeutics
32. Table Products & Services of AstraZeneca
33. Table Products & Services of GlaxoSmithKline (GSK)
34. Table Products & Services of Carna Biosciences
35. Table Products & Services of Celgene Corporation
36. Table Products & Services of Eternity Bioscience

- 37. Table Products & Services of Jasco Pharmaceuticals
- 38. Table Market Distribution of Major Players
- 39. Table Global Major Players Sales Revenue (Million USD) 2017-2020e
- 40. Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
- 41. Table Global Non-Tyrosine Kinase Inhibitors Market Forecast (Million USD) by Region 2021f-2026f
- 42. Table Global Non-Tyrosine Kinase Inhibitors Market Forecast (Million USD) Share by Region 2021f-2026f
- 43. Table Global Non-Tyrosine Kinase Inhibitors Market Forecast (Million USD) by Demand 2021f-2026f
- 44. Table Global Non-Tyrosine Kinase Inhibitors Market Forecast (Million USD) Share by Demand 2021f-2026f

List Of Figures

LIST OF FIGURES

1. Figure Global Non-Tyrosine Kinase Inhibitors Market Size under the Impact of COVID-19, 2017-2021f (USD Million)
2. Figure Global Non-Tyrosine Kinase Inhibitors Market by Region under the Impact of COVID-19, 2017-2021f (USD Million)
3. Figure Global Non-Tyrosine Kinase Inhibitors Market by Product Type under the Impact of COVID-19, 2017-2021f (USD Million)
4. Figure Global Non-Tyrosine Kinase Inhibitors Market by Demand under the Impact of COVID-19, 2017-2021f (USD Million)
5. Figure Global Non-Tyrosine Kinase Inhibitors Production by Region under the Impact of COVID-19, 2021-2026 (USD Million)
6. Figure Global Non-Tyrosine Kinase Inhibitors Consumption by Region under the Impact of COVID-19, 2021-2026 (USD Million)
7. Figure Global Non-Tyrosine Kinase Inhibitors Consumption by Type under the Impact of COVID-19, 2021-2026 (USD Million)
8. Figure North America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
9. Figure Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
10. Figure Asia-Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
11. Figure South America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
12. Figure Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
13. Figure mTOR Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
14. Figure RAF/MEK Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
15. Figure CDK Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
16. Figure Liver Cancer Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
17. Figure Respiratory Cancer Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
18. Figure Brain Cancer Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

19. Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
20. Figure U.S. Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
21. Figure Canada Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
22. Figure Mexico Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
23. Figure mTOR Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
24. Figure RAF/MEK Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
25. Figure CDK Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
26. Figure Liver Cancer Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
27. Figure Respiratory Cancer Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
28. Figure Brain Cancer Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
29. Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
30. Figure Germany Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
31. Figure UK Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
32. Figure France Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
33. Figure Italy Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
34. Figure Rest of Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
35. Figure mTOR Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
36. Figure RAF/MEK Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
37. Figure CDK Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
38. Figure Liver Cancer Segmentation Market Size (USD Million) 2017-2021f and Year-

over-year (YOY) Growth (%) 2018-2021f

39. Figure Respiratory Cancer Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

40. Figure Brain Cancer Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

41. Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

42. Figure China Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

43. Figure India Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

44. Figure Japan Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

45. Figure South Korea Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

46. Figure Southeast Asia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

47. Figure Australia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

48. Figure Rest of Asia Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

49. Figure mTOR Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

50. Figure RAF/MEK Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

51. Figure CDK Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

52. Figure Liver Cancer Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

53. Figure Respiratory Cancer Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

54. Figure Brain Cancer Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

55. Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

56. Figure Brazil Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

57. Figure Argentina Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

58. Figure Rest of Latin America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
59. Figure mTOR Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
60. Figure RAF/MEK Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
61. Figure CDK Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
62. Figure Liver Cancer Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
63. Figure Respiratory Cancer Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
64. Figure Brain Cancer Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
65. Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
66. Figure GCC Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
67. Figure North Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
68. Figure South Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
69. Figure Rest of Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
70. Figure mTOR Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
71. Figure RAF/MEK Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
72. Figure CDK Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
73. Figure Liver Cancer Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- 74.F

I would like to order

Product name: Non-Tyrosine Kinase Inhibitors Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

Product link: <https://marketpublishers.com/r/N2C8E988FAD7EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N2C8E988FAD7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

